OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-05-31-accounts

Trustees’ Annual Report for the period

From 1/6/2024 Period start date To 31/5/2025 Period end date

Charity name: HaemSTAR: Haematology Specialist Training, Audit and Research

Charity registration number: 1199224

Objectives and Activities

SORP reference
Summary of the purposes of
the charity as set out in its
governing document		 Para 1.17 To protect and preserve the health of patients suffering
from haematological conditions by:
a)
the promotion of clinical research into Non-
Malignant Haematology in the United Kingdom,
the causes, prevention and treatment of
haematological conditions on terms that the
results of such research will be published.
b)
the advancement of education and training of
junior doctors and haematologists to give them
the skills to become the chief and principal
investigators of the future.'
Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.		 Para 1.17 and
1.19		 During 1/6/24 to 31/5/25 we conceived, developed, ran,
supported and/or wrote up nine projects. All of these
projects further our charitable objects because
1)
they all require project management (which is
used to train junior doctors and haematologists
in how to be researchers and principal
investigators) and
2)
they ultimately result in the publication of
research findings that benefit patients.
Projects take several years to complete from the time of
inception. Activity completed from 1/6/24 to 31/5/25 is
highlighted inred:
AudHIT – Heparin- Induced Thrombocytopaenia
audit
•
Type of study:retrospective, multi-centred
national audit
•
Topic:National Audit evaluating diagnosis and
management of HIT against BSH guidelines.
Included use of 4Ts score, lab testing and
treatment pathways.
•
HaemSTAR role:Led by Dr Richard Buka.
Data collection coordinated via the trainee
network.
•
Size of study:National, multi-centre.
•
Main outcomes:Preliminary finding:
suboptimal diagnostic work-up in suspected
HIT
•
Outputs:Presented at National conference –
BSH 2025 – poster. Ongoing analysis and
future publication expected.
MoM-ITP (Maternal ITP/neonatal outcomes) – began
in March 2024.
•
Type of study:Prospective, multi-centre
national audit.
• Topic:Management of delivery and neonatal
monitoring in mothers with ITP. Comparison to
international consensus guidelines.
• HaemSTAR role:Co-led by Dr Nick Fordham
and Dr Olga Tsiamita with HaemSTAR. Run
and coordinator by the HaemSTAR network.
Funding from Grifols (non-promotional grant).
• Size of study:Target 100 patients.
• Main outcomes:Data collection complete
• Outputs:Publication expected
ATOMM (Anticoagulation for ThrOmbosis in Multiple
Myeloma)
• Type of study:National, retrospective audit.
• Topic:Audit of thromboprophylaxis in newly
diagnosed myeloma in the UK. To help inform
the evidence-based selection of
thromboprophylactic agents for patients
receiving first line myeloma treatment.
• HaemSTAR role:Lead: Tom Bull and the
ATOMM committee. Lead site: Cambridge
University Hospitals. Project developed in
conjunction with myeloma patients. Supported
by HaemSTAR with project management by
BiCOPS. Funded by Myeloma UK.
• Size of study:>2000 patients
• Main outcomes:Data collection ran from
March to July 2025. Data cleaning completed
December 2025. Hoping to present results
during 2026.
• Outputs:Data analysis underway
A short questionnaire has followed on from this initial
data collection. The survey is not limited to those
involved in ATOMM, but was aimed at anyone who is
regularly responsible for prescribing thromboprophylaxis
for myeloma patients.
TXA in Heavy Menstrual Bleeding with acute VTE
• Type of study:Survey of clinician practice,
observational data collection, future RCT
development.
• Topic:To evaluate the use of tranexamic acid
in women with heavy menstrual bleeding and
recent VTE.
• HaemSTAR role:Lead by Dr Eman Hassan.
No funding specified. Distributed by
HaemSTAR. Data analysis – Dr Eman Hassan.
No funding.
• Size of study:102 respondents
• Main outcomes:Apixaban preferred
anticoagulant for patients with HMB. Wide
variation in practice re timing of TxA use; 35%
prescribed it any time following initiation of
anticoagulation, 12% delayed its use for 3
months; 8% would never give it. 47% of
respondents advise to discontinue COCP
following VTE (whilst treated with
anticoagulants). 63% of respondents willing to
participate in a study of TxA ≤ 4 weeks
following VTE.
• Outputs:Paper March 2025: Thrombosis
Research: Disparities in menstrual bleeding
management during acute venous
thromboembolism treatment: A review of UK
practice and a call for clinical studies
HaemSTAR RAPIDO (A ‘Flash-Mob’ UK national
audit of the use of Reversal Agents in Patients
antIcoagulated with Direct Oral anticoagulants)
• Type of study:Retrospective National Audit.
• Topic:Compliance with BSH guidelines for the
use of reversal agents inpatients with major
haemorrhage who are taking direct oral
anticoagulants (DOACs).
• HaemSTAR role:Conceived and developed
by Dr Richard Buka (Stoke) and HaemSTAR.
Run by HaemSTAR. Data management
provided by BiCOPS. Funded by AstraZeneca
and the Dudley Leukaemia Unit Appear Fund.
• Size of study:2265 patients.
• Main outcomes:875 patients had GI
haemorrhage, 1012 had ICH. Median age 81
years. Median time from bleed onset to
reversal: 6.5 hours. Median time from last dose
of anticoagulation to reversal: 16.0 hours. 1001
of 1253 non-ICH bleeds fulfilled criteria for
major hemorrhage. Propensity score-matched
analysis of 494 patients with GI haemorrhage:
outcomes similar for andexanet alfa and four
factor prothrombin complex concentrate.
Incidence of stroke was significantly higher
with andexanet alfa.
• Outputs:Poster presentation at ASH Annual
Congress 2024 and BSHT Annual Conference
2025.Paper in process within the above
timeframe. Publication anticipated March 2026.
Abstract published November 5th2024.
MATRON (Maternal Audit on ThRombolysis
Outcome and DecisioN) - Survey
• Type of study:UK Clinician Survey
• Topic:The use of thrombolysis for pregnant
women with venous thromboembolism.
• Size of study:Survey with 70 responses.
Target audit responses of 200 patients
(completion Q2 2025).
• HaemSTAR Role:Conceived and developed
by Dr Giulia Simini (Royal London &
HaemSTAR). Run by HaemSTAR. Data
management by HaemSTAR.
• Main outcomes:Survey: CDT available to
74%, Surgical thrombectomy to 62% and
ECMO to 52% of respondents. Only 50% of
sites had specific guidelines on CDT and 17%
had no guidelines on managing pregnancy
associated PE. 38% had received specific
training on pregnancy-associated PE. 22% had
had training in systemic thrombolysis. 46% did
not have access to PERT with geographic
inconsistency. Audit in planning stages.
• Outputs:Survey manuscript published July
2025. In process within above timeframe.
Abstract published 14thMay 2024.
MATRON – Audit
• Type of study:Pan-UK audit. Retrospective.
• Topic:Aiming to assess management of high
risk and intermediate-high risk pulmonary
embolism in pregnancy and puerperium.
• Size of study:75 cases.
• HaemSTAR role:Conceived and developed
by Dr Giulia Simini (Royal London &
HaemSTAR). Run by HaemSTAR. Data
management by HaemSTAR.
• Main outcomes:data analysis ongoing.
• Outputs:Further analysis ongoing as of May
2025. Planning a second window for data
collection. Planning abstract submission for
ISTH 2026.
VAMP: Venesection vs Active Monitoring in
Secondary Polycythaemia
• Type of study:International clinician survey,
retrospective audit and then prospective
clinical trial.
• Topic:Venesection in patients with idiopathic
and secondary erythrocytosis
• Size of study:Survey with 123 responses (90
senior clinicians). Audit with 206 patients.
Prospective study in development.
• HaemSTAR Role:Conceived and developed
by Dr Richard Buka, Dr Bernard Maybury and
Dr Pip Nicolson (Birmingham & HaemSTAR),
Run by HaemSTAR, Data management by
HaemSTAR.
• Main outcomes:
o
Survey: minority venesect routinely,
2/3 will venesect in specific
circumstances; 1/3 never venesect.
More likely to venesect if previous
thrombosis or if headache or visual
disburbance. Majority use Hct
threshold of 0.55 but some use 0.6
and most have Hct target of <0.55
but some use <0.52. 85% willing to
consider entering patients into a trial.
o
Audit: 2360 patients screened, 206
eligible. 27% no EPO done. Minority
have RCM scan done. Most given
appropriate lifestyle advice. 60%
never venesected. 29% of those
venesected have no target Hct
documented. Mean Hct reduces prior
to diagnosis and further reduces
regardless of venesection. 5 year
thrombosis rate 12% regardless of
venesection vs no venesection or
whether polycythaemia resolves.
Cancer and prior unprovoked VTE
are the only factors to predict
subsequent thrombosis.
• Outputs:Audit poster presentation at BSH
2024.Manuscript accepted and predicted
publication in June 2025.
Anticoagulation at the end of life
• Type of study:National survey
• Topic:To gauge current practice and decision-
making surrounding anticoagulation at the end
of life. Hoping to pave the way for further
research in the area.
• Size of study:186 responses.
• HaemSTAR involvement:led by Dr Thomas
Shevlin and Dr Olga Tsiamita. Distributed by
HaemSTAR network.
• Main outcomes:56% of respondents routinely
seek advice from colleagues regarding these
decisions. 53% of respondents reported having
worried about the medico-legal implications of
discontinuing OAC, 52% of whom reported the
worries influence their decision making. 83%
would feel more confident in broaching this
subject if national guidance existed.
• Outputs: Publication: clinical medicine: Are we
comfortable managing oral anticoagulation at
the end of life? A national survey of secondary
care clinicians in the UK
In set up:
Perioperative management of Haemophilia B
‘FIX-Surg’
The primary objectives of the project are to audit the
haemostatic management of patients with haemophilia B
who are undergoing surgery against World Federation of
Haemophilia guidelines. Project running from April to
June 2025.
PaTRIC– Practice of Transfusion In Cirrhosis
PaTRIC is the UK arm of an international audit
evaluating real-world transfusion practices in
hospitalised patients with cirrhosis, focusing on platelet
and coagulation factor replacement. Anticipated data
collection March to June 2026.
TRUTH- sTeroids in warm aUToimmune Haemolytic
anaemia
TRUTH is a UK-wide audit of the management of warm
autoimmune haemolytic anaemia, focusing on
corticosteroid use. Aiming to open in March 2026.
AQuA- Acquired Haemophilia A – National Audit
Acquired haemophilia A is a rare, potentially life-
threatening bleeding disorder caused by autoantibodies
against FVIII. There are national BSH guidelines for the
‘Diagnosis and Management of Acquired Coagulation
Factor Inhibitor’ from 2013, and international consensus
recommendations from 2020, but management options
have changed considerably over this time and local
practices across the UK differ.
The HaemSTAR hub-and-spoke model is an ideal
platform for looking at rare diseases. AQuA is a
multicentre, national audit, comprising a 5-year
retrospective review of patients diagnosed with acquired
haemophilia A. We aim to include a minimum of 6
comprehensive care centres in the audit.
FUNDING AWARDS
From the ISTH London 2022 Legacy Fund we were able
to fund travel grants for trainees attending conferences
(e.g. EAHAD 2025) and the International fellowship
programme (Nigeria collaboration). This enabled
conference attendance, presentation of HaemSTAR
work, professional development and ongoing
international collaboration work.
Awards were through competitive application with award
by grant panel.
Funding was obtained and used for specific research
studies:
-
RAPIDO (Astra Zeneca and Dudley fund)
-
MOM-ITP (Grifols)
-
A2PLS (Bayer)
This supported data management and study
infrastructure.
Charity income detailed below.
CONFERENCE
In association with Hartley Taylor and the Post
ISTH/ASH UK Update meeting we hosted a HaemSTAR
Update day on 10/2/25 at The Liner Hotel, Liverpool.
This comprised updates and results on current
HaemSTAR projects and plenary talks from experts on
research in global health settings, ‘blood is the heart of
medicine’ and National haemovigilance updates (SHOT).
Very positive feedback. Attendance was free and was
increased from the year before. Free registration for
HaemSTAR conference helped with travel
reimbursement to enable attendance as well supporting
the invited speakers.
HaemSTAR breakfast Briefings
In collaboration with ‘The Limbic’ we provide monthly,
free, online webinars led by experts with interactive Q&A
segments. These are targeted at haematology trainees
and consultants. They are predominantly focused on
non-malignant haematology education and research
translation. Topics in the last year have included VTE in
pregnancy, genetic testing in haemostasis, iron
deficiency, PNH and new therapies.
The Limbic reimburse £5 to HaemSTAR for every
attendee that fills in feedback surveys.
PODCAST- Don’t Just Read the Abstract
Hosted by Dr Richard Buka and Dr Pip Nicolson, the
focus of discussion is of recent research papers in non-
malignant haematology, critical appraisal of evidence
and expert guest interviews. The purpose of it is to help
trainees go beyond abstracts – to understand methods,
bias and clinical impact.
BLOG
HaemSTAR maintains a regular blog with contents
which include conference reflections, trainee
experiences, project updates, and thought pieces on
collaboration and research.
BSH CONFERENCE SESSION
HaemSTAR delivered a dedicated session within the
BSH 2025 programme. This included an overview of
HaemSTAR, project presentations, how to get involved
and research education. This raised awareness of
ongoing HaemSTAR studies, research opportunities and
encouraged new project proposals. HaemSTAR also
had its own stall with promotion of current and upcoming
studies, HaemSTAR events, signposting to website and
project sign-up and networking with potential
collaborators.
Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit		 Para 1.18 N/A – not relevant to our charitable
purposes

Additional information (optional) You may choose to include further statements where relevant about:

SORP reference N/A Para 1.38 Policy on grant making N/A Para 1.38 Policy on social investment including program related investment N/A Para 1.38 Contribution made by volunteers N/A Other

Achievements and Performance

SORP reference

Summary of the
main achievements
of the charity,
identifying the
difference the
charity’s work has
made to the
circumstances of its
beneficiaries and any
wider benefits to
society as a whole.		 Para 1.20 FUNDING
Received the following grants:
-
Research Grant from AstraZeneca UK for
RAPIDO: £17,600 (part of previous £88,000
grant)
-
Research Grant from SOBI UK: for FIX-SURG
£36,750
-
Research Grant from Takeda for AcQa: £6,500
-
Research Grant from SOBI UK: For Real world
data in ITP project: £18,375
-
Administrative support (unrestricted grant)
from Takeda: £5,000
PUBLICATIONS
•
Nicolson PLR, Belete M, Hawes R, Fowler N,
Toh CH. Alternative routes into clinical
research: a guide for early career doctors.
BMJ. 2024;385:e076414.
•
Hassan E, Sutton D, Buka RJ, Lowe GC,
Nandra T, Jacob N, Rose L, Alhamdi Y,
HaemSTAR Collaborators, Nicolson PLR.
Disparities in Menstrual Bleeding Management
During Acute Venous Thromboembolism
Treatment: A Review of UK Practice and a Call
for Clinical Studies. Thromb Res 2025
https://doi.org/10.1016/j.thromres.2025.109258

Additional information (optional) You may choose to include further statements where relevant about:

Achievements against
objectives set		 Para 1.41
Performance of fundraising
activities against objectives
set		 Para 1.41
Investment performance
against objectives		 Para 1.41
Other

Financial Review

Financial Review
Review of the charity’s
financial position at the end
of the period		 Para 1.21 Amount held at start of reporting period:
£70,338
Income from all sources (including interest):
£92,401
All spending: £47,130
Amount held at the end of the reporting
period: £141,352
Statement explaining the
policy for holding reserves
stating why they are held		 Para 1.22 Cash in bank at 31/5/24 was £70,338 in unrestricted
funds and £25,742 in restricted funds for ISTH Legacy
fund spending
committed spending for 2024-25 comprises website
hosting fees of approximately £350, podcast hosting
fees of £200, accountancy fees of ~£150 and
administration costs (paid for the time of our
administrator) of ~£3000. This is all covered by the
administrative grant of £5000 from Takeda and does not
represent a financial risk. We also aim to apply for
additional sponsorship of the podcast for when the Sobi
sponsorship ends in 2025.
In 2023-24 we expanded our ability to fund registrars to
attend conferences. £19,200 of this comes from the
ISTH Legacy fund and we are able to use this until
2026. It is unlikely that costs will exceed this figure.
The educational webinars are a source of an
approximately £1200 annual cost. This is voluntary
however and can be stopped if there are insufficient
funds.
The HaemSTAR Update Day is now a recurring event
but this is organised through Hartley Taylor and they
secure industry support for the meeting. The only
HaemSTAR costs are voluntary and will not go ahead if
there are insufficient funds.
All the projects currently active are fully funded.
However we would like to run unfunded projects by
using money underspent from other projects and also
pump prime our pipeline by employing a project/data
manager through the University of Birmingham at a cost
of approximately £70,000 per year. This is not yet
feasible and will not go ahead unless there are sufficient
funds. The funding for this will be reviewed on an annual
basis and no commitments beyond 1 year will be made
to ensure there is no financial risk to the charity.
Amount of reserves held Para 1.22 £0
Reasons for holding zero
reserves		 Para 1.22 We do not have a reserve policy.
Details of fund materially in
deficit		 Para 1.24 N/A
Explanation of any
uncertainties about the
charity continuing as a going
concern		 Para 1.23 Nil uncertainties. N/A

Additional information (optional) You may choose to include further statements where relevant about:

The charity’s principal sources of funds (including Para 1.47 any fundraising) Investment policy and objectives including any Para 1.46

social investment policy
adopted
A description of the principal
risks facing the charity		 Para 1.46
Other

Structure, Governance and Management

Description of charity’s
trusts:		 Nil
Type of governing document
(trust deed, royal charter)		 Para 1.25 Constitution
How is the charity
constituted?
(e.g unincorporated
association, CIO)		 Para 1.25 Unincorporated Association
Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees		 Para 1.25 Nil.

Additional information (optional) You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction Para 1.51 and training of trustees The charity’s organisational structure and any wider Para 1.51 network with which the charity works Relationship with any related Para 1.51 parties Other

Reference and Administrative details

Charity name HaemSTAR: Haematology Specialist Training, Audit
and Research
Other name the charity uses HaemSTAR
Registered charity number 1199224
Charity’s principal address Office 129, Institute of Biomedical Research
Edgbaston
Birmingham
B15 2TT

Names of the charity trustees who manage the charity

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20		 Trustee name Office (if any) Dates acted if not for whole
year		 Name of person (or body) entitled
to appoint trustee (if any)
PhillipLR Nicolson President
Richard J Buka Chair
Andrew J Doyle
EmilyMillen
Tom Bull

– Corporate trustees names of the directors at the date the report was approved

Director name

Name of trustees holding title to property belonging to the charity

Trustee name Dates acted if not for whole year

Funds held as custodian trustees on behalf of others

Description of the assets Nil held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of
adviser
Name
Address		 Type of
adviser
Name
Address		 Type of
adviser
Name
Address
Name of chief executive or names of senior staff members (Optional information)

Exemptions from disclosure

Reason for non-disclosure of key personnel details

N/A

Other optional information

Declarations

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s) Full name(s) Dr Phillip LR Nicolson Position (eg Secretary, President Chair, etc) Date 27/3/2026

HaemSTAR HaemSTAR HaemSTAR 1199224 CC16a
Receipts andpayments accounts
For the period
from		 01/06/2024 To 31/05/2025
Section A Receipts and payments
Unrestricted
funds
to the nearest £
A1 Receipts
35-daySavings Interest(28/6/2024)
167
95-daySavings Interest(28/6/2024)
32
Business Reserve Interest(28/6/2024)
11
35-daySavings Interest(31/7/2024)
197
Business Reserve Interest(31/7/2024)
13
95-daySavings Interest(31/7/2024)
36
AstraZeneca UK Ltd (Unrestricted
Researchgrant - RAPIDO 23/08/2024)
17,600
35-daySavings Interest(30/8/2024)
180
(
30/08/2024)
8
Bank interest(95-DayAccount 30/08/2024) 31
Limbic Digital (Webinar income
09/09/2024)
2,440
PayPal(Donation – small 11/09/2024)
0
Bank interest(35-DayAccount 30/09/2024) 134
Bank interest(95-DayAccount 30/09/2024) 84
Bank interest (Business Reserve
30/09/2024)
10
S P Hibbs (Refund – overpayment
18/10/2024)
0
Bank interest(35-DayAccount 31/10/2024) 89
Bank interest (Business Reserve
31/10/2024)
12
Bank interest(95-DayAccount 31/10/2024) 126
Limbic Digital (Webinar donation income
08/11/2024)
70
Bank interest(35-DayAccount 29/11/2024) 80
Bank interest (Business Reserve
29/11/2024)
11
Bank interest(95-DayAccount 29/11/2024) 118
Bank interest(35-DayAccount 31/12/2024) 89
Bank interest (Business Reserve
31/12/2024)
12
Bank interest(95-DayAccount 31/12/2024) 131
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(08/01/2025)
19,950
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(17/01/2025)
18,375
Takeda (via LLXEU/Payce) –
sponsorship/grant(31/01/2025)
5,000
Bank interest(35-DayAccount 31/01/2025) 84
Bank interest (Business Reserve
31/01/2025)
11
Bank interest(95-dayaccount 31/01/2025)
126
Takeda (via LLXEU/Payce) –
sponsorship/grant(28/02/2025)
6,500
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(28/02/2025)
9,188
Bank interest(35-DayAccount 28/02/2025) 72
Bank interest (Business Reserve
28/02/2025)
10
Bank interest(95-DayAccount 28/02/2025) 231
Bank interest(35-DayAccount 31/03/2025) 73
Bank interest (Business Reserve
31/03/2025)
11
Bank interest(95-DayAccount 31/03/2025) 256
Dr P Nicolson (Gift Aided donation
01/04/2025)
750
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(25/04/2025)
9,188
Bank interest(35-DayAccount 30/04/2025) 15
Bank interest (Business Reserve
30/04/2025)
10
Bank interest(95-DayAccount 30/04/2025) 249
Helen Apperley (Meal deposits refund
01/05/2025)
350
Bank interest(35-DayAccount 30/05/2025) 14
Bank interest(95-DayAccount 30/05/2025) 249
Bank interest (Business Reserve
30/05/2025)
9
-		 Restricted
funds
to the nearest £		 Endowment
funds
to the nearest £		 Total funds
to the nearest £
35-daySavings Interest(28/6/2024) 167 - - 167 -
95-daySavings Interest(28/6/2024) 32 - - 32 -
Business Reserve Interest(28/6/2024) 11 - - 11 -
35-daySavings Interest(31/7/2024) 197 - - 197 -
Business Reserve Interest(31/7/2024) 13 - - 13 -
95-daySavings Interest(31/7/2024) 36 - - 36 -
AstraZeneca UK Ltd (Unrestricted
Researchgrant - RAPIDO 23/08/2024)		 17,600 - 17,600 -
35-daySavings Interest(30/8/2024)
(		 180 180
30/08/2024) 8 8
Bank interest(95-DayAccount 30/08/2024) 31 31
Limbic Digital (Webinar income
09/09/2024)		 2,440 2,440
PayPal(Donation – small 11/09/2024) 0 0
Bank interest(35-DayAccount 30/09/2024) 134 134
Bank interest(95-DayAccount 30/09/2024) 84 84
Bank interest (Business Reserve
30/09/2024)		 10 10
S P Hibbs (Refund – overpayment
18/10/2024)		 0 0
Bank interest(35-DayAccount 31/10/2024) 89 89
Bank interest (Business Reserve
31/10/2024)		 12 12
Bank interest(95-DayAccount 31/10/2024) 126 126
Limbic Digital (Webinar donation income
08/11/2024)		 70 70
Bank interest(35-DayAccount 29/11/2024) 80 80
Bank interest (Business Reserve
29/11/2024)		 11 11
Bank interest(95-DayAccount 29/11/2024) 118 118
Bank interest(35-DayAccount 31/12/2024) 89 89
Bank interest (Business Reserve
31/12/2024)		 12 12
Bank interest(95-DayAccount 31/12/2024) 131 131
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(08/01/2025)		 19,950 19,950
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(17/01/2025)		 18,375 18,375
Takeda (via LLXEU/Payce) –
sponsorship/grant(31/01/2025)		 5,000 5,000
Bank interest(35-DayAccount 31/01/2025) 84 84
Bank interest (Business Reserve
31/01/2025)		 11 11
Bank interest(95-dayaccount 31/01/2025) 126 126
Takeda (via LLXEU/Payce) –
sponsorship/grant(28/02/2025)		 6,500 6,500
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(28/02/2025)		 9,188 9,188
Bank interest(35-DayAccount 28/02/2025) 72 72
Bank interest (Business Reserve
28/02/2025)		 10 10
Bank interest(95-DayAccount 28/02/2025) 231 231
Bank interest(35-DayAccount 31/03/2025) 73 73
Bank interest (Business Reserve
31/03/2025)		 11 11
Bank interest(95-DayAccount 31/03/2025) 256 256
Dr P Nicolson (Gift Aided donation
01/04/2025)		 750 750
Swedish Orphan Biovitrum (SOBI UK) –
sponsorship/grant(25/04/2025)		 9,188 9,188
Bank interest(35-DayAccount 30/04/2025) 15 15
Bank interest (Business Reserve
30/04/2025)		 10 10
Bank interest(95-DayAccount 30/04/2025) 249 249
Helen Apperley (Meal deposits refund
01/05/2025)		 350 350
Bank interest(35-DayAccount 30/05/2025) 14 14
Bank interest(95-DayAccount 30/05/2025) 249 249
Bank interest (Business Reserve
30/05/2025)		 9 9
- -
1		 - - -

CCXX R1 accounts (SS)

Sub total(Gross income for
AR)

92,401		 - - 92,401 54,928
A2 Asset and investment sales,
(see table).		 -
-
- - -
- - - -
Sub total - - - - -
Total receipts
A3 Payments
92,401 - - 92,401 54,928
29
-
29
799
29
29
2,490
29
106
84
1,413
29
29
100
19
29

152
100

29

80
1,943

450
29

195
153
39
111
45
120
27,535
29
115
2,263

257
740
150
Squarespace(Web domain 6/6/24) - - 29 -
ISTH Legacy (Guilia Simini EHA 21/6/24) 352 - 352 -
Squarespace(Web domain 6/7/24) - - 29 -
Currys (Laptop for Administrator 8/7/24) - - 799 -
Squarespace(Website 06/08/2024) 29
Nkem Jacob (ISTH Legacy Fund payment
09/08/2024)		 1,500 1,500
Squarespace(Website 06/09/2024) 29
Mrs H C Apperley (Admin invoice
04/10/2024)		 2,490
Stephen Hibbs (Update Day – Nigeria
Lemfi 04/10/2024)		 598 598
Squarespace(Website 07/10/2024) 29
Richard Buka (Novartis Meeting Train
Expenses 18/10/2024)		 106
Pip Nicolson (Novartis train expenses
18/10/2024)		 84
Jasmine Mak (ASH 2024 travel 8/10/2024) 1,413
Stephen Hibbs (ISTH Legacy Fund - Aisha
Oct 25/10/2024)		 17 17
Squarespace(Website 06/11/2024) 29
Stephen Hibbs (ISTH Legacy Fund –
Aisha Oct 22/11/2024)		 17 17
Walaa Saad (ISTH Legacy Fund payment
29/11/2024)		 589 589
Squarespace(Website 06/12/2024) 29
HMRC(Corporation Tax 10/12/2024) 100
Squarespace (Website –
additional/annual? 16/12/2024)		 19
Squarespace(Website 06/01/2025) 29
Troy-Barnes (ISTH-ASH Legacy Fund
payment 13/01/2025)		 902 902
Stephen Hibbs (ISTH Legacy Fund – Aisha
Dec 13/01/2025)		 19 19
Acast (Podcast hosting service 14/01/2025) 152
HMRC(Corporation Tax 27/01/2025) 100
Stephen Hibbs (ISTH Legacy Fund – Aisha
Jan 31/01/2025)		 19 19
Squarespace(Website 06/02/2025) 29
C Arts Bar, Hope St Liverpool (HaemSTAR
update day drinks 11/02/2025)		 80
Mr Richard J Buka (ASH 2025 expenses -
RAPIDO Presentation 21/02/2025)		 1,943
Chloe Merrion (ISTH Legacy Fund
payment 24/02/2025)		 728 728
Amazon (update day speaker gifts (6 x £75
24/02/2025)		 450
Squarespace(Website 06/03/2025) 29
Stephen Hibbs (ISTH Legacy Fund – Aisha
Feb 10/03/2025)		 20 20
O Tsiamita (Update Day travel 2025
payment 14/03/2025)		 195
J Wolf (Update Day travel 2025 payment
14/03/2025)		 153
Stephen Hibbs (Update Day travel 2025
14/03/2025)		 39
Laura Knox (Update Day 2025 payment
14/03/2025)		 111
Cam Edmead (HaemTRIAL admin invoice
21/03/2025)		 45
Willows Accountancy (Invoice 5763
21/03/2025)		 120
Stephen Hibbs (ISTH Legacy – Aisha Mar
21/03/2025)		 19 19
University of Birmingham (Invoice
72142196 re RAPIDO 28/03/2025)		 27,535
Squarespace(Website 07/04/2025) 29
BHR NHS Trust (M Egolum placement,
ISTH Legacy11/04/2025)		 500 500
C Crossette-Thumbiah (Update Day 2025
reimbursement 23/04/2025)		 115
Mrs H C Apperley (Admin invoice – Apr
2025 23/04/2025)		 2,263
Janine Collins (ISTH Legacy Fund payment
24/04/2025)		 584 584
Stephen Hibbs (ISTH Legacy Nigeria – for
M Igolum 28/04/2025)		 430 430
Motel One (BSH P Nicolson hotel
28/04/2025)		 257
Ka Pao Glasgow (restaurant – BSH
conference meal? 29/04/2025)		 740
U Bello (ISTH Legacy – Igolum hotel
01/05/2025)		 65 65
Stephen Hibbs (ISTH Legacy – Aisha Apr
01/05/2025)		 18 18
Amazon (BSH Dragons Den prizes
01/05/2025)		 2 150

CCXX R2 accounts (SS)

Squarespace(Website 07/05/2025) 29 29
TfL Oyster (M Igolum travel ISTH Legacy–
London 09/05/2025)		 20 - 20 -
TfL Oyster (M Igolum travel ISTH Legacy –
London 12/05/2025)		 10 - 10 -
Mrs H C Apperley (ISTH Legacy – Igolum
accommodation 16/05/2025)		 909 - 909 -
TfL Oyster (M Igolum travel ISTH Legacy –
London 19/05/2025)		 10 - 10 -
- - - - -
**Sub total ** 39,804 7,326 - 47,130 39,541
A4 Asset and investment
purchases, (see table)
- - - -
- - - -
**Sub total ** - - - - -
Total payments
Net of receipts/(payments)
A5 Transfers between funds
A6 Cash funds last year end
Cash funds this year end
39,804 7,326 - 47,130 39,541
52,597 - 7,326 - 45,271 15,388
- - - - -
70,338 25,742 - 96,081 -
122,935 18,416 - 141,351 15,388

Section B Statement of assets and liabilities at the end of the period

Categories
Signed by one or two trustees on
behalf of all the trustees
B5 Liabilities
B3 Investment assets
B2 Other monetary assets
B4 Assets retained for the
charity’s own use
B1 Cash funds		 Details Unrestricted
funds
to nearest £		 Restricted
funds
to nearest £		 Endowment
funds
to nearest £
Money in bank account (31/5/25) 141,352 - -
- - -
- - -
Total cash funds
(agree balances with receipts and payments
account(s))
Details		 141,352 - -
Agreement Error Agreement Error OK
Unrestricted
funds
to nearest £		 Restricted
funds
to nearest £		 Endowment
funds
to nearest £
- - -
- - -
- - -
- - -
- - -
- - -
Details Fund to which
asset belongs		 Cost (optional) Current value
(optional)
- -
- -
- -
- -
- -
Details Fund to which
asset belongs		 Cost (optional) Current value
(optional)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Details Fund to which
liability relates		 Amount due
(optional)		 When due
(optional)
-
-
-
-
-
Signature Print Name
Date of
approval
P NICO LSON
~~3~~

CCXX R3 accounts (SS)

23/03/2026

Independent examiner's report on the accounts

Section A Independent Examiner’s Report

Report to the trustees Charity Name HaemSTAR: Haematology Specialty Training, Audit and Research On accounts for the year 31/05/2025 1199224 ended Set out on pages Two to Four

I report to the trustees on my examination of the accounts of the above charity (“the Trust”) for the year ended 31 May 2025

Responsibilities and As the charity's trustees, you are responsible for the preparation of the basis of report accounts in accordance with the requirements of the Charities Act 2011 (“the Act”).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent I have completed my examination. I confirm that no material matters have examiner's statement come to my attention in connection with the examination (other than that disclosed below *) which gives me cause to believe that in, any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: Date: 23 March 2026 Name: Mark Fellows (Willows Accountancy Ltd) Relevant professional Fellow Member of Association of Accounting Technicians qualification(s) or body (if any): Address: 172 Watling Street, Bridgtown, Staffordshire, WS11 0BD

Oct 2018

1

IER

Section B Disclosure

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose .

Oct 2018

2

IER